Ownership and insider activity for MacroGenics, Inc. (MGNX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear...
Price
| Price | $4.08 |
| Market Cap | $259M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-19 | Peters Jeffrey Stuart | S-Sale | 31,105 | $129K |
| 2026-08-17 | Bonvini Ezio | M-Exempt | 40,000 | $104K |
| 2026-08-17 | Bonvini Ezio | M-Exempt | 40,000 | $104K |
| 2026-05-19 | O'Brien Federica F. | A-Award | 22,000 | $99K |
| 2026-05-18 | O'Brien Federica F. | M-Exempt | 3,750 | |
| 2026-05-19 | O'Brien Federica F. | A-Award | 3,750 | |
| 2026-05-18 | O'Brien Federica F. | M-Exempt | 3,750 | |
| 2026-05-19 | Jackson Scott Thomas | A-Award | 22,000 | $99K |
| 2026-05-18 | Jackson Scott Thomas | M-Exempt | 3,750 | |
| 2026-05-19 | Jackson Scott Thomas | A-Award | 3,750 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84.1M | $211.7M | $220.1M | $126.5M | $181.1M | $123.5M | $108.9M | $101.0M | $182.8M | $57.2M |
| Short-term Investments | $192.9M | $93.4M | $12.7M | $89.3M | $91.4M | $120.1M | $45.5M | $128.8M | $18.8M | $132.7M |
| Receivables | $2.8M | $13.6M | $29.6M | $12.7M | $23.1M | $10.4M | $56.2M | $10.4M | $4.3M | $13.4M |
| Inventory | -$8.0M | 0 | 0 | 0 | 0 | $4.4M | $1.5M | $1.2M | 0 | $7.9M |
| Total Current Assets | $283.9M | $322.3M | $269.1M | $239.8M | $312.6M | $279.6M | $222.2M | $251.3M | $217.5M | $219.9M |
| Property, Plant & Equipment | $18.0M | $50.0M | $56.7M | $68.4M | $61.5M | $54.3M | $56.9M | $45.7M | $42.6M | $35.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $311.3M | $373.9M | $332.1M | $312.5M | $378.7M | $335.2M | $289.5M | $298.4M | $261.7M | $256.8M |
| Accounts Payable | $4.0M | $2.5M | $4.0M | $4.3M | $8.0M | $15.5M | $4.9M | $6.4M | $5.0M | $4.8M |
| Short-term Debt | $1.6M | $298000 | 0 | 0 | 0 | 0 | $4.7M | 0 | 0 | $5.2M |
| Total Current Liabilities | $27.3M | $49.8M | $59.9M | $45.2M | $50.7M | $74.6M | $48.6M | $56.1M | $55.5M | $43.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $70.0M |
| Total Liabilities | $42.5M | $74.6M | $89.3M | $81.9M | $82.9M | $95.6M | $147.5M | $145.8M | $145.6M | $201.3M |
| Retained Earnings | -$292.7M | -$312.3M | -$490.3M | -$642.1M | -$771.8M | -$973.9M | -$1.09B | -$1.10B | -$1.17B | -$1.24B |
| Total Equity | $268.8M | $299.2M | $242.9M | $230.6M | $295.9M | $239.6M | $142.0M | $152.6M | $116.1M | $55.6M |
| Total Debt | $1.9M | $298000 | 0 | $30.6M | $29.2M | $25.5M | $34.8M | $34.0M | $37.5M | $106.8M |
| Net Debt | -$275.1M | -$304.8M | -$232.9M | -$185.2M | -$243.3M | -$218.1M | -$119.5M | -$195.8M | -$164.2M | -$83.2M |
| Working Capital | $256.6M | $272.5M | $209.2M | $194.6M | $261.9M | $205.0M | $173.6M | $195.2M | $162.0M | $176.8M |
Financial Health
| Debt / Equity | 0.82 |
| Current Ratio | 2.96 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -6.01 |
Profitability
| Return on Equity | -31.27% |
| Return on Invested Capital | -2.36% |
| Return on Assets | -4.22% |
| Gross Margin | 50.44% |
| Operating Margin | -24.30% |
| Net Margin | -8.70% |
Related companies: CLNN · CNTB · CNTX · COYA · IFRX · ORMP · OVID
Explore sector: Healthcare · Biotechnology
More sections of MGNX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks